These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 6443011)

  • 21. Effects of immunosuppression and benzonidazole on Trypanosoma cruzi parasitism during experimental acute Chagas' disease.
    Okumura M; Mester M; Iriya K; Amato Neto V; Gama-Rodrigues J
    Transplant Proc; 1994 Jun; 26(3):1587-9. PubMed ID: 8030049
    [No Abstract]   [Full Text] [Related]  

  • 22. Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review.
    Rev Inst Med Trop Sao Paulo; 2020; 62():e52err. PubMed ID: 32844906
    [No Abstract]   [Full Text] [Related]  

  • 23. Polymerase chain reaction (PCR) as a laboratory tool for the evaluation of the parasitological cure in Chagas disease after specific treatment.
    Britto C; Cardoso A; Silveira C; Macedo V; Fernandes O
    Medicina (B Aires); 1999; 59 Suppl 2():176-8. PubMed ID: 10668261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerance of benznidazole in a United States Chagas Disease clinic.
    Miller DA; Hernandez S; Rodriguez De Armas L; Eells SJ; Traina MM; Miller LG; Meymandi SK
    Clin Infect Dis; 2015 Apr; 60(8):1237-40. PubMed ID: 25601454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Integral treatment of congenital Chagas disease: the Bolivian experience ].
    Suárez E; Alonso-Vega C; Torrico F; Córdova M
    Rev Soc Bras Med Trop; 2005; 38 Suppl 2():21-3. PubMed ID: 16482807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Protective effect of benznidazole against parasite reactivation in patients chronically infected with Trypanosoma cruzi and treated with corticoids for associated diseases].
    Rassi A; Amato Neto V; de Siqueira AF; Ferriolli Filho F; Amato VS; Rassi Júnior A
    Rev Soc Bras Med Trop; 1999; 32(5):475-82. PubMed ID: 10881079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heart rate variability in chronic Chagas patients before and after treatment with benznidazole.
    Oliveira LF; Silva VJ; Lages-Silva E; Molina RJ; Fuzissaki J; Niederhaur S; Prata A; Correia D
    Auton Neurosci; 2010 Dec; 158(1-2):118-22. PubMed ID: 20558113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolerance of benznidazole in treatment of Chagas' disease in adults.
    Pinazo MJ; Muñoz J; Posada E; López-Chejade P; Gállego M; Ayala E; del Cacho E; Soy D; Gascon J
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4896-9. PubMed ID: 20823286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA Gives First-Ever Approval of Drug To Treat Chagas' Disease.
    Morrow T
    Manag Care; 2017 Nov; 26(11):38-40. PubMed ID: 29185981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Benznidazole in the primary chemoprophylaxis of the reactivation of Chagas' disease in chronic chagasic patients using corticosteroids at immunosuppressive doses: is there sufficient evidence for recommending its use?].
    Nishioka Sde A
    Rev Soc Bras Med Trop; 2000; 33(1):83-5. PubMed ID: 10881124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of Chagas disease with benznidazole and thioctic acid].
    Roldán EJ
    Medicina (B Aires); 2005; 65(1):85-6; author reply 86-7. PubMed ID: 15830800
    [No Abstract]   [Full Text] [Related]  

  • 32. Chronic Chagas disease with advanced cardiac complications in Japan: Case report and literature review.
    Imai K; Maeda T; Sayama Y; Osa M; Mikita K; Kurane I; Miyahira Y; Kawana A; Miura S
    Parasitol Int; 2015 Oct; 64(5):240-2. PubMed ID: 25744336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitrypanosomal therapy for chronic Chagas' disease.
    Bestetti RB; Cardinalli-Neto A
    N Engl J Med; 2011 Sep; 365(13):1258-9; author reply 1259. PubMed ID: 21991909
    [No Abstract]   [Full Text] [Related]  

  • 34. Antitrypanosomal therapy for chronic Chagas' disease.
    Garcia-Bournissen F; Altcheh J
    N Engl J Med; 2011 Sep; 365(13):1258; author reply 1259. PubMed ID: 21991908
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevention of congenital Chagas through treatment of girls and women of childbearing age.
    Moscatelli G; Moroni S; García-Bournissen F; Ballering G; Bisio M; Freilij H; Altcheh J
    Mem Inst Oswaldo Cruz; 2015 Jun; 110(4):507-9. PubMed ID: 25993401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arthritis and benznidazole: more closely related than we thought.
    Aldasoro E; Pinazo MJ; Oliveira I; Munoz J; Posada E; Requena-Méndez A; Serret N; Gascon J
    Antimicrob Agents Chemother; 2015 Jan; 59(1):727-9. PubMed ID: 25385100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are imidazolic drugs effective in the treatment of chronic Chagas cardiomyopathy?
    Vallejo M; Reyes PA
    Salud Publica Mex; 2003; 45(4):243-4. PubMed ID: 12974040
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of compliance to congenital Chagas disease treatment: results of a randomised trial in Bolivia.
    Chippaux JP; Salas-Clavijo AN; Postigo JR; Schneider D; Santalla JA; Brutus L
    Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):1-7. PubMed ID: 23296694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of Chagas disease].
    Abitbol H
    An R Acad Nac Med (Madr); 1981; 98(4):755-8. PubMed ID: 6808853
    [No Abstract]   [Full Text] [Related]  

  • 40. Posaconazole versus benznidazole for chronic Chagas' disease.
    Bestetti RB; Restini CB
    N Engl J Med; 2014 Sep; 371(10):966. PubMed ID: 25184873
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.